Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MannKind cuts lengthy Afresa NDA

Executive Summary

MannKind had been pushing to submit an NDA for Afresa - the only inhaled insulin still in development - by the end of February. However, the Valencia, Calif. company announced Feb. 26 it is delaying the filing by approximately three weeks to reduce the size of the dossier by "several tens of thousands" of pages to make the document more reviewer-friendly; the "back-up" data will be available if requested by FDA. Announcing the specifics for the delay may not be the wisest decision. As Diabetic Investor's David Kliff notes Feb. 27, "This statement just might peak the agency's curiosity and create the impression that there might be something in those tens of thousands of pages that the company does not want the agency to see." MannKind has been retooling the positioning of Afresa as "ultra rapid-acting" insulin to separate it from Pfizer's failed Exubera (1"The Pink Sheet" DAILY, Feb. 18, 2009)
Advertisement

Related Content

NDA Almost Ready, MannKind Exubera(nt) About Chances For Inhaled-Insulin Partner
NDA Almost Ready, MannKind Exubera(nt) About Chances For Inhaled-Insulin Partner

Topics

Advertisement
UsernamePublicRestriction

Register

PS050756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel